• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Peterson Caryn

    3/20/26 4:20:55 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOSS alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Peterson Caryn

    (Last)(First)(Middle)
    3115 MERRYFIELD ROW, SUITE 120

    (Street)
    SAN DIEGO CALIFORNIA 92121

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Gossamer Bio, Inc. [ GOSS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    EVP, Regulatory Affairs
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/19/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (Right to Buy)$2.8803/19/2026D(1)506,250 (2)01/01/2036Common Stock506,250(1)0D
    Stock Option (Right to Buy)$1.1303/19/2026D(1)440,000 (2)03/03/2035Common Stock440,000(1)0D
    Stock Option (Right to Buy)$0.9703/19/2026D(1)375,000 (2)01/01/2034Common Stock375,000(1)0D
    Stock Option (Right to Buy)$0.83803/19/2026D(1)125,000 (2)11/19/2033Common Stock125,000(1)0D
    Stock Option (Right to Buy)$1.2103/19/2026D(1)157,500 (2)03/19/2033Common Stock157,500(1)0D
    Stock Option (Right to Buy)$2.1603/19/2026D(1)157,500 (2)12/06/2032Common Stock157,500(1)0D
    Stock Option (Right to Buy)$1.3603/19/2026D(1)126,667 (2)01/05/2032Common Stock126,667(1)0D
    Stock Option (Right to Buy)$1.3603/19/2026D(1)21,167 (2)04/16/2031Common Stock21,167(1)0D
    Stock Option (Right to Buy)$1.3603/19/2026D(1)18,834 (2)02/25/2031Common Stock18,834(1)0D
    Stock Option (Right to Buy)$1.3603/19/2026D(1)22,784 (2)02/14/2030Common Stock22,784(1)0D
    Stock Option (Right to Buy)$1.3603/19/2026D(1)9,167 (2)12/23/2029Common Stock9,167(1)0D
    Stock Option (Right to Buy)$1.3603/19/2026D(1)32,334 (2)03/25/2029Common Stock32,334(1)0D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)506,250 (2)01/01/2036Common Stock506,250(1)506,250D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)440,000 (2)03/03/2035Common Stock440,000(1)440,000D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)375,000 (2)01/01/2034Common Stock375,000(1)375,000D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)125,000 (2)11/19/2033Common Stock125,000(1)125,000D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)157,500 (2)03/19/2023Common Stock157,500(1)157,500D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)157,500 (2)12/06/2032Common Stock157,500(1)157,500D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)126,667 (2)01/05/2032Common Stock126,667(1)126,667D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)21,167 (2)04/16/2031Common Stock21,167(1)21,167D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)18,834 (2)02/25/2031Common Stock18,834(1)18,834D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)22,784 (2)02/14/2030Common Stock22,784(1)22,784D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)9,167 (2)12/23/2029Common Stock9,167(1)9,167D
    Stock Option (Right to Buy)$0.4503/19/2026A(1)32,334 (2)03/25/2029Common Stock32,334(1)32,334D
    Explanation of Responses:
    1. Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
    2. This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
    Remarks:
    /s/ Jeff Boerneke, Attorney-in-Fact03/20/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $GOSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GOSS

    DatePrice TargetRatingAnalyst
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    1/28/2026$9.00Overweight
    Barclays
    9/10/2025$9.00Neutral → Buy
    UBS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    6/25/2024$9.00Outperform
    Oppenheimer
    4/5/2024$4.00Outperform
    Wedbush
    More analyst ratings

    $GOSS
    SEC Filings

    View All

    SEC Form EFFECT filed by Gossamer Bio Inc.

    EFFECT - Gossamer Bio, Inc. (0001728117) (Filer)

    3/19/26 12:15:30 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POS AM filed by Gossamer Bio Inc.

    POS AM - Gossamer Bio, Inc. (0001728117) (Filer)

    3/17/26 4:09:29 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Gossamer Bio, Inc. (0001728117) (Filer)

    3/17/26 4:04:01 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

    - Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic options and capital allocation - - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the Company evaluates implications of PROSERA results - - The Company implemented a reduction in force to align resources with near-term priorities - - Cash, cash equivalents and marketable securities totaled $137 million at year-end 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH)

    3/17/26 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective January 5th, 2026, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The award was granted as an indu

    1/8/26 5:30:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Aranda Richard

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:22:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Peterson Caryn

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:20:55 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Smith Robert Paul Jr

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:19:57 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hasnain Faheem bought $250,282 worth of shares (372,000 units at $0.67) (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    6/24/24 5:52:18 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO/CFO Giraudo Bryan bought $59,110 worth of shares (100,000 units at $0.59) (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    6/20/24 8:21:38 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Gossamer Bio from Outperform to Market Perform and set a new price target of $1.00

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Leadership Updates

    Live Leadership Updates

    View All

    Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

    - Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.

    12/5/23 7:01:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise

    11/29/23 7:01:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),

    10/3/23 4:08:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Financials

    Live finance-specific insights

    View All

    Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

    - Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic options and capital allocation - - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the Company evaluates implications of PROSERA results - - The Company implemented a reduction in force to align resources with near-term priorities - - Cash, cash equivalents and marketable securities totaled $137 million at year-end 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH)

    3/17/26 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

    - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash equivalents and marketable securities totaled $180 million as of September 30 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing

    11/5/25 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 4:40:26 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 9:55:14 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    8/2/24 6:30:57 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care